Efficacy of the combination of monoclonal antibodies against the SARS-CoV-2 Beta and Delta variants

  1. Boonkrai, Chatikorn
  2. Cotrone, Thomas S.
  3. Chaisuriyong, Watchadaporn
  4. Tantawichien, Terapong
  5. Thisyakorn, Usa
  6. Fernandez, Stefan
  7. Hunsawong, Taweewun
  8. Reed, Matthew
  9. Wongtangprasert, Tossapon
  10. Audomsun, Thittaya
  11. Phakham, Tanapati
  12. Attakitbancha, Chadaporn
  13. Saelao, Pijitra
  14. Focht, Dorota
  15. Kimbung, Raymond
  16. Welin, Martin
  17. Malik, Aijaz Ahmad
  18. Pisitkun, Trairak
  19. Srisawat, Nattachai ORCID logo

Download
journal.pone.0284173.pdf 1,90MB
WeightNameValue
1000 Titel
  • Efficacy of the combination of monoclonal antibodies against the SARS-CoV-2 Beta and Delta variants
1000 Autor/in
  1. Boonkrai, Chatikorn |
  2. Cotrone, Thomas S. |
  3. Chaisuriyong, Watchadaporn |
  4. Tantawichien, Terapong |
  5. Thisyakorn, Usa |
  6. Fernandez, Stefan |
  7. Hunsawong, Taweewun |
  8. Reed, Matthew |
  9. Wongtangprasert, Tossapon |
  10. Audomsun, Thittaya |
  11. Phakham, Tanapati |
  12. Attakitbancha, Chadaporn |
  13. Saelao, Pijitra |
  14. Focht, Dorota |
  15. Kimbung, Raymond |
  16. Welin, Martin |
  17. Malik, Aijaz Ahmad |
  18. Pisitkun, Trairak |
  19. Srisawat, Nattachai |
1000 Erscheinungsjahr 2023
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2023-05-04
1000 Erschienen in
1000 Quellenangabe
  • 18(5):e0284173
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1371/journal.pone.0284173 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10159178/ |
1000 Ergänzendes Material
  • https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0284173#sec032 |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • The pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is currently the biggest healthcare issue worldwide. This study aimed to develop a monoclonal antibody against SARS-CoV-2 from B cells of recovered COVID-19 patients, which might have beneficial therapeutic purposes for COVID-19 patients. We successfully generated human monoclonal antibodies (hmAbs) against the receptor binding domain (RBD) protein of SARS-CoV-2 using developed hybridoma technology. The isolated hmAbs against the RBD protein (wild-type) showed high binding activity and neutralized the interaction between the RBD and the cellular receptor angiotensin-converting enzyme 2 (ACE2) protein. Epitope binning and crystallography results displayed target epitopes of these antibodies in distinct regions beneficial in the mix as a cocktail. The 3D2 binds to conserved epitopes among multi-variants. Pseudovirion-based neutralization results revealed that the antibody cocktail, 1D1 and 3D2, showed high potency in multiple variants of SARS-CoV-2 infection. In vivo studies showed the ability of the antibody cocktail treatment (intraperitoneal (i.p.) administration) to reduce viral load (Beta variant) in blood and various tissues. While the antibody cocktail treatment (intranasal (i.n.) administration) could not significantly reduce the viral load in nasal turbinate and lung tissue, it could reduce the viral load in blood, kidney, and brain tissue. These findings revealed that the efficacy of the antibody cocktail, 1D1 and 3D2, should be further studied in animal models in terms of timing of administration, optimal dose, and efficacy to mitigate inflammation in targeted tissue such as nasal turbinate and lung.
1000 Sacherschließung
gnd 1206347392 COVID-19
lokal Enzyme-linked immunoassays
lokal SARS CoV 2
lokal Monoclonal antibodies
lokal Hybridomas
lokal Antibody therapy
lokal Euthanasia
lokal Antibodies
1000 Fächerklassifikation (DDC)
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/Qm9vbmtyYWksIENoYXRpa29ybg==|https://frl.publisso.de/adhoc/uri/Q290cm9uZSwgVGhvbWFzIFMu|https://frl.publisso.de/adhoc/uri/Q2hhaXN1cml5b25nLCBXYXRjaGFkYXBvcm4=|https://frl.publisso.de/adhoc/uri/VGFudGF3aWNoaWVuLCBUZXJhcG9uZw==|https://frl.publisso.de/adhoc/uri/VGhpc3lha29ybiwgVXNh|https://frl.publisso.de/adhoc/uri/RmVybmFuZGV6LCBTdGVmYW4=|https://frl.publisso.de/adhoc/uri/SHVuc2F3b25nLCBUYXdlZXd1bg==|https://frl.publisso.de/adhoc/uri/UmVlZCwgTWF0dGhldw==|https://frl.publisso.de/adhoc/uri/V29uZ3RhbmdwcmFzZXJ0LCBUb3NzYXBvbg==|https://frl.publisso.de/adhoc/uri/QXVkb21zdW4sIFRoaXR0YXlh|https://frl.publisso.de/adhoc/uri/UGhha2hhbSwgVGFuYXBhdGk=|https://frl.publisso.de/adhoc/uri/QXR0YWtpdGJhbmNoYSwgQ2hhZGFwb3Ju|https://frl.publisso.de/adhoc/uri/U2FlbGFvLCBQaWppdHJh|https://frl.publisso.de/adhoc/uri/Rm9jaHQsIERvcm90YQ==|https://frl.publisso.de/adhoc/uri/S2ltYnVuZywgUmF5bW9uZA==|https://frl.publisso.de/adhoc/uri/V2VsaW4sIE1hcnRpbg==|https://frl.publisso.de/adhoc/uri/TWFsaWssIEFpamF6IEFobWFk|https://frl.publisso.de/adhoc/uri/UGlzaXRrdW4sIFRyYWlyYWs=|https://orcid.org/0000-0002-8544-8132
1000 (Academic) Editor
1000 Label
1000 Förderer
  1. Ratchadapiseksompotch Fund |
  2. http://dx.doi.org/10.13039/501100010724 |
  3. Education and Research Management Committee |
  4. Thai Red Cross Society |
  5. Sirivadhanabhakdi foundation |
1000 Fördernummer
  1. RA(P0)001/64
  2. -
  3. 64-112
  4. -
  5. -
1000 Förderprogramm
  1. -
  2. -
  3. -
  4. -
  5. -
1000 Dateien
1000 Förderung
  1. 1000 joinedFunding-child
    1000 Förderer Ratchadapiseksompotch Fund |
    1000 Förderprogramm -
    1000 Fördernummer RA(P0)001/64
  2. 1000 joinedFunding-child
    1000 Förderer http://dx.doi.org/10.13039/501100010724 |
    1000 Förderprogramm -
    1000 Fördernummer -
  3. 1000 joinedFunding-child
    1000 Förderer Education and Research Management Committee |
    1000 Förderprogramm -
    1000 Fördernummer 64-112
  4. 1000 joinedFunding-child
    1000 Förderer Thai Red Cross Society |
    1000 Förderprogramm -
    1000 Fördernummer -
  5. 1000 joinedFunding-child
    1000 Förderer Sirivadhanabhakdi foundation |
    1000 Förderprogramm -
    1000 Fördernummer -
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6452842.rdf
1000 Erstellt am 2023-06-16T14:42:45.223+0200
1000 Erstellt von 337
1000 beschreibt frl:6452842
1000 Bearbeitet von 25
1000 Zuletzt bearbeitet 2023-06-21T09:11:19.250+0200
1000 Objekt bearb. Wed Jun 21 09:11:18 CEST 2023
1000 Vgl. frl:6452842
1000 Oai Id
  1. oai:frl.publisso.de:frl:6452842 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source